6'-Sialyllactose Sodium Salt from Derivative Strains of Escherichia coli Authorized for Market Placement in the EU as a Novel Food

The European Commission (EC) has granted authorization for the placement of 6'-Sialyllactose sodium salt, produced using derivative strains of Escherichia coli BL21(DE3), on the market within the Union. This authorization is based on the inclusion of 6'-Sialyllactose sodium salt in the Union list of novel foods outlined in Implementing Regulation (EU) 2017/2470. 
The amendment to the Annex of Implementing Regulation (EU) 2017/2470 is made in accordance with the Annex specified in this new Regulation. It should be noted that only the company Chr. Hansen A/S (15) is permitted to place the novel food mentioned in Article 1 on the market within the Union. This authorization is valid for a period of five years starting from June 4, 2023, unless another applicant successfully obtains authorization for the same novel food without relying on the protected scientific data outlined in Article 3 or with the agreement of Chr. Hansen A/S.